J&J's Zytiga gets OK in Scotland; Novartis touts long-term Cosentyx results; Amgen's Prolia scores in head-to-head osteoporosis trial;

@FiercePharma: Study: Elephants rarely get cancer--and that could boost human oncology research. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sanofi's Kansas City, MO, plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce

@CarlyHFierce: Backlash rages on over Purdue's pediatric OxyContin approval. Story | Follow @CarlyHFierce

> Johnson & Johnson's ($JNJ) prostate cancer treatment Zytiga won approval from the Scottish Medicines Consortium, which means it can be routinely used in that country; the drug still lacks routine approval in England and Wales. Release

> Novartis ($NVS) unveiled new data showing that a majority of psoriasis patients using Cosentyx were able to maintain clear or almost clear skin for three years. Release

> Amgen's ($AMGN) Prolia delivered larger gains in bone-mineral density than the IV bisphosphonate drug zoledronic acid in postmenopausal women with osteoporosis who'd previously been treated with bisphosphonates. Release

> New U.S. drug approvals promise better second-half results for Indian drugmakers, analysts said, compared with the first six months of this year. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Procyrion raises $10M to get minimally invasive mini heart pump in the clinic. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week from #AdvaMed15: CMS has 30 people to evaluate 30,000 diagnostic tests, but more FDA oversight is likely. More | Follow @VarunSaxena2

@EmilyWFierce: The latest from Advera Health Analytics on Alzheimer's drug safety. ICYMI from FiercePharma | Follow @EmilyWFierce

> NuVasive gets FDA blessing for spinal cord surgical device. Report

> Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More

> Neurosurgeons hope brain implants can be used to treat array of mental disorders. Article

Biotech News

@FierceBiotech: Lilly upgrades its NYC research hub, adding 50 jobs in an immuno-oncology push. News | Follow @FierceBiotech

@JohnCFierce: How many big swings and misses does John Lechleiter get at $LLY? | Follow @JohnCFierce

@DamianFierce: Tired of writing about $LLY today so here's a hypoglycemia deal you can read about yourself. Press release | Follow @DamianFierce

> Novartis buys a bigger stake in Gamida, stopping short of a $600M plunge. Report

> Lilly pulls the plug on a would-be blockbuster in its latest pipeline peril. Story

> Voyager braves turbulent market waters with an $86M gene therapy IPO. Article

Animal Health News

> Study: Elephants rarely get cancer--and that could boost human oncology research. More

> Ceva urges mass vaccination against bird flu at global animal-health gathering. Story

> FDA seeks comments on potential scheduling change for ketamine. Item

> California sets strictest U.S. standards for antibiotics use in livestock. Article

> CalTech team creates one-time contraceptive vaccine for feral animals. Report

Biotech IT News

> NIH gives UCSF $10M to build mobile data collection platform. News

> GSK finds 21M mentions of its drugs in trawl of social media. Report

> ResearchKit-enabled project sets out to track real-world effectiveness of hep C drugs. Story

> UBiome taps Apple ecosystem to broaden microbiome data-gathering drive. Article

> Is Google a competitor or partner to Big Pharma? Roche's CEO doesn't know, yet. More

Pharma Marketing News

> Baxalta joins biosim makers eyeing a piece of AbbVie's Humira. More

> Biogen's top commercial exec leaves amid Tecfidera sales trouble. Report

> Roche leads the pack at ECTRIMS with standout data on new MS drug. Item

> Bill seeks to add nurse practitioners, PAs to Sunshine Act reporting. Story

> Pharma's digital desires thwarted by clunky organizations, lack of skilled employees. Article

And Finally... Merck KGaA says it's betting its cancer pipeline can rescue it from a decline in sales of its top-selling multiple sclerosis drug Rebif. Report